Tag archive for ‘Clal Biotechnology Industries’
Gil Tanenbaum On Friday, January 9th, 2015

Gamida Cell Has Success With Its Nicord Blood Cancer Medication

Israel’s Gamida Cell, a developer of cell therapy technologies and products for transplantation and adaptive immune therapy, announced that the first person has been successfully transplanted with cryopreserved More...

Koby Yeshayahou On Sunday, December 21st, 2014

Medivation takes up $335 million Curetech licensing option

– The agreement gives Medivation the license to develop and commercialize Curetech’s pidilizumab cancer treatment. –   Medivation has decided to exercise the option granted it by Curetech More...

Gali Weinreb On Wednesday, December 17th, 2014

BioLineRX signs Novartis strategic cooperation deal

– Novartis will invest $10 million in BioLineRX for a 12.8% stake. They will select three projects for joint development. –   Drug development company BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX) More...

Gil Tanenbaum On Monday, October 27th, 2014

Clal Biotech Sells Pidilizumab Cancer Treatment Rights to Medivation

Israel’s Clal Biotechnology Industries has sold the exclusive worldwide commercialization rights for its cancer treatment pidilizumab to the American company Medivation. The rights are held by Clal subsidiary More...

Wordpress site Developed by Fixing WordPress Problems